|
Amgen and Zhejiang Beta Pharma announce planned joint venture in China
|
10 May 2013 |
|
Amgen announces top-line results of phase 3 talimogene laherparepvec trial in melanoma
|
20 March 2013 |
|
Amgen's full year 2012 revenues increased 11 percent to $17.3 billion
|
23 January 2013 |
|
Amgen's second quarter 2012 revenues increased 13 percent to $4.5 billion
|
26 July 2012 |
|
Amgen's BiTE® antibody blinatumomab (AMG 103) achieved high rate of complete response
|
17 May 2012 |
|
Cancer Support Community launches national program to assist patients with cancer
|
10 May 2012 |
|
Amgen's first quarter 2012 revenue increased 9 percent to $4.0 billion
|
25 April 2012 |
|
Amgen to acquire privately held KAI Pharmaceuticals
|
10 April 2012 |
|
Amgen and AstraZeneca announce collaboration to jointly develop and commercialize clinical-stage inflammation portfolio
|
03 April 2012 |
|
Schwartz Center Receives $500,000 Grant from the Amgen Foundation
|
06 March 2012 |
|
Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion
|
29 January 2012 |
|
Amgen to Acquire Micromet
|
25 January 2012 |
|
Amgen and Watson Announce Collaboration to Develop and Commercialize Oncology Biosimilars
|
19 December 2011 |
|
Prescribing Physicians, Patients and Institutions no Longer Required to Enroll in Nplate® NEXUS Program
|
06 December 2011 |
|
Enbrel® (etanercept) Patent Issued
|
22 November 2011 |
|
Amgen's Third Quarter Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent
|
27 October 2011 |
|
Prolia® (Denosumab) Phase 2 Extension Study
|
19 September 2011 |
|
Amgen's Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion
|
01 August 2011 |
|
XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
|
15 July 2011 |
|
Amgen and UCB Team Up with NASA
|
06 July 2011 |